Abstract mTOR (mammalian target of rapamycin) forms two distinct types of complex, mTORC (mTOR complex) 1 and 2. Rapamycin inhibits some of the functions of mTORC1, whereas newly developed mTOR kinase inhibitors interfere with the actions of both types of complex. We have explored the effects of rapamycin and mTOR kinase inhibitors on general protein synthesis and, using a new stable isotope-labelling method, the synthesis of specific proteins. In HeLa cells, rapamycin only had a modest effect on total protein synthesis, whereas mTOR kinase inhibitors decreased protein synthesis by approx. 30 %. This does not seem to be due to the ability of mTOR kinase inhibitors to block the binding of eIFs (eukaryotic initiation factors) eIF4G and eIF4E. Analysis of the effects of the inhibitors on the synthesis of specific proteins showed a spectrum of behaviours. As expected, synthesis of proteins encoded by mRNAs that contain a 5 -TOP (5 -terminal oligopyrimidine tract) was impaired by rapamycin, but more strongly by mTOR kinase inhibition. Several proteins not known to be encoded by 5 -TOP mRNAs also showed similar behaviour. Synthesis of proteins encoded by 'non-TOP' mRNAs was less inhibited by mTOR kinase inhibitors and especially by rapamycin. The implications of our findings are discussed.
mTOR regulates proteins involved in mRNA translation
mTOR (mammalian target of rapamycin) is a serine/threonine protein kinase that forms two distinct types of complexes with partner proteins [1] . These are termed mTORC (mTOR complex) 1 and 2 and differ in their protein composition, substrate specificity and control ( Figure 1 ). In particular, mTORC1 contains raptor (regulatory associated protein of mTOR) that interacts with substrates for mTORC1, recruiting them to the complex to be phosphorylated by the catalytic domain of mTOR. In place of the raptor, mTORC2 contains a different protein, rictor (rapamycin-insensitive companion of mTOR). A further key difference is that treatment of cells with rapamycin rapidly impairs signalling through mTORC1 but not mTORC2 (although it can interfere with mTORC2 after longer times [2] ).
The best-characterized substrates for mTORC1 are involved in protein synthesis (mRNA translation) and/or its control (Figure 1 ). mTORC1 phosphorylates the S6Ks (S6 kinases) S6K1 and S6K2, contributing to their activation [3] . S6Ks in turn phosphorylate several proteins linked to Key words: mammalian target of rapamycin (mTOR), mRNA, pulsed stable isotope labelling of proteins with amino acids in cell culture (pSILAC), rapamycin, translation, 5 -terminal oligopyrimidine tract (5 -TOP). Abbreviations used: 4E-BP, eukaryotic initiation factor 4E-binding protein; eEF2, eukaryotic elongation factor 2; eIF4B, eukaryotic initiation factor 4B; mTOR, mammalian target of rapamycin; mTORC, mTOR complex; Pdcd4, programmed cell death 4; pSILAC, pulsed stable isotope labelling of proteins with amino acids in cell culture; S6K, S6 kinase; raptor, regulatory associated protein of mTOR; rictor, rapamycin-insensitive companion of mTOR; 5 -TOP, 5 -terminal oligopyrimidine tract; UTR, untranslated region. 1 To whom correspondence should be addressed (email c.g.proud@soton.ac.uk).
mRNA translation including ribosomal protein S6, eEF2 (eukaryotic elongation factor 2) kinase, eIF4B (eukaryotic initiation factor 4B) and Pdcd4 (programmed cell death 4). The physiological role of S6 phosphorylation remains unclear, although there is evidence that it may affect the size of some cells [4] . S6K-mediated phosphorylation of eEF2 kinase inhibits its activity, which promotes translation elongation. eIF4B and Pdcd4 are positive and negative regulators respectively of the RNA helicase eIF4A [5, 6] . eIF4A helps to unravel secondary structure in the 5 -UTRs (untranslated regions) of mRNAs. Such 'secondary structure' inhibits efficient translation and occurs in a number of mRNAs that encode key regulators of cellular function, e.g. stages of the cell cycle. eIF4A is recruited to the 5 -end of the mRNA through its interaction with the scaffold protein eIF4G. In turn, eIF4G is brought to the mRNA through its interaction with eIF4E, the protein that binds the 5 -terminal 7-methylguanosine 'cap' structure (reviewed in [7] ).
The association of eIF4G with eIF4E is regulated through another substrate of mTORC1, the 4E-BPs (eIF4E-binding proteins). There are three 4E-BPs in mammals, of which 4E-BP1 is easily the best understood. When bound to eIF4E, 4E-BP1 prevents eIF4E's association with eIF4G (since 4E-BPs and eIF4G occupy overlapping sites in eIF4E). 4E-BP1 undergoes hierarchical phosphorylation by mTORC1 at several sites. Some sites are phosphorylated by mTORC1 in response to amino acids (which stimulate mTORC1 signalling) and do not affect eIF4E/4E-BP1 binding (Thr 37 /Thr 46 in human 4E-BP1). Others (Ser 65 /Thr 70 ) appear to be phosphorylated by mTORC1 in response to its further activation by, e.g., insulin or serum, and their The components of mTORC1 and mTORC2 are shown. Connections between mTORC1 and the protein synthesis machinery are shown including direct substrates (italic, bold) and links, to the control of translation factors and ribosome biogenesis. Green arrows, activation; red lines, inhibition; grey dashed arrows, probable connections whose molecular components remain to be identified.
phosphorylation disrupts the binding of 4E-BP1 to eIF4E, allowing the latter protein to bind eIF4G. Since eIF4E is bound to the 5 -end of the mRNA, this allows the recruitment of eIF4A and other partners for eIF4G, such as PABP [poly(A)-tail-binding protein] [8] . The complex of eIF4E, eIF4G and eIF4A is often termed 'eIF4F'. Recent results have demonstrated that 4E-BPs are involved in the control of cell proliferation by mTORC1, probably because they affect (impair) the translation of proteins required for cell-cycle progression [9] . Consistent with the above, rapamycin blocks cell proliferation by preventing progression into S-phase. Indeed, various types of 'cancer cells' are very sensitive to the antiproliferative effects of rapamycin, leading to a high level of interest in using rapamycin and related compounds for cancer therapy. However, rapamycin only affects a subset of the functions of mTORC1: for example, phosphorylation of Thr 37 /Thr 46 is often unaffected by rapamycin, even though their phosphorylation is mediated via mTOR/mTORC1 [10] . This fact and other considerations have prompted the development of compounds that inhibit the protein kinase activity of mTOR, thus interfering with (as far as we know) all functions of mTORC1 and mTORC2. Two examples are PP242 [11] and AZD8055 [12] .
In addition to controlling the activity of the translational machinery, mTORC1 also positively regulates the translational capacity of the cell by promoting ribosome biogenesis. It does so by promoting the activities of the RNA polymerases that make rRNA (polymerases I and III) and by stimulating the translation of mRNAs for ribosomal proteins. These mRNAs contain a 5 -terminal sequence (tract) of pyrimidines [5 -TOP (5 -terminal oligopyrimidine tract)] that impairs their translation under basal conditions, this impairment being overcome when the mTORC1 pathway is activated (reviewed in [13] ). However, it is still not known how mTORC1 signalling promotes the translation of 5 -TOP mRNAs.
mTOR kinase inhibitors inhibit general protein synthesis much more strongly than rapamycin does
Given that rapamycin and mTOR kinase inhibitors were expected to have different effects on signalling downstream of mTOR, we were interested to explore their effects on protein synthesis. First, we examined their effects on known targets of mTORC1 in serum-fed HeLa cells. Rapamycin and mTOR kinase inhibitors, such as PP242, each completely inhibited the phosphorylation of S6, as expected. In contrast, they had differing effects on different sites in 4E-BP1: rapamycin did not alter the phosphorylation of Thr 37/46 , whereas mTOR kinase inhibitors did. No inhibition of Thr 70 phosphorylation was seen with these compounds. Interestingly, rapamycin and PP242 also had markedly different effects on the association of eIF4E with its partners, eIF4G and 4E-BP1/2. mTOR kinase inhibitors caused a marked increase in binding of eIF4E to 4E-BP1 and 4E-BP2, and strongly inhibited association with eIF4G. In contrast, rapamycin had little effect on binding to 4E-BP1/2 and did not decrease the association of eIF4E with eIF4G. Thus mTOR kinase inhibitors, but not rapamycin, inhibit the formation of initiation factor complexes containing eIF4E, eIF4G and presumably other components.
We next studied the effects of these compounds on protein synthesis, which was assessed by measuring the incorporation of radiolabelled methionine into protein over short periods of time (up to 2 h). This was to avoid effects on ribosomal biogenesis and mRNA transcription, which will become stronger at later times. Rapamycin had little effect, whereas mTOR kinase inhibitors inhibited protein synthesis by approx. 30 %. Importantly, these results imply that S6K-mediated phosphorylation of S6, eIF4B and eEF2 does not affect overall protein synthesis in the short term. Even at 6 h of treatment, rapamycin had no effect on protein synthesis rates in HeLa cells. The findings also imply that other effects of mTOR kinase inhibitors do affect protein synthesis. Such effects could either be rapamycin-insensitive effects of mTORC1 or functions of mTORC2. However, Thoreen et al. [14] showed that the inhibitory effect of another mTOR kinase inhibitor, Torin1, was the same in rictor − / − and wild-type cells, implying that the inhibitory effects of mTOR kinase inhibitors on protein synthesis are not mediated through mTORC2.
The likeliest mechanism to explain the differences in the effects of mTOR kinase inhibitors compared with rapamycin on protein synthesis is that the effects of the former reflect their ability to inhibit eIF4E/eIF4G binding, which is not impaired by rapamycin in HeLa cells. To test this idea, we overexpressed eIF4E in HeLa cells, arguing that the excess eIF4E would 'mop up' any hypophosphorylated 4E-BP1, allowing the remaining eIF4E to continue to bind eIF4G. Analysis of the proteins bound to eIF4E in response to rapamycin or mTOR kinase inhibitors confirmed that such compounds do not impair eIF4E/eIF4G binding in cells that ectopically express eIF4E. Nonetheless, mTOR kinase inhibitors still inhibited translation in such cells. This implies that the inhibition of protein synthesis caused by such compounds is not due to the loss of eIF4E-eIF4G complexes, but rather to other factors that are regulated by mTORC1 in a rapamycin-insensitive manner.
Application of a stable isotope-labelling approach to examine the control of the synthesis of specific proteins by mTOR
We were particularly interested in examining the effects of rapamycin and mTOR kinase inhibitors on the synthesis of specific proteins, given, for example, that classes of mRNAs containing a 5 -TOP or structured 5 -UTRs might be expected to be regulated through mTORC1 signalling. To do this, we developed a technique, similar to that reported by Selbach et al. [15] , in which newly made proteins are tagged, in living cells, with heavy isotope-labelled arginine or lysine residues. After tryptic digestion, peptides are analysed by MS. Each peptide appears in two forms, one containing normal 'light' arginine or lysine residues, the other containing the heavy version of one or both of these amino acids. For the ratios of 'heavy' to 'light' for multiple peptides from the same parent protein, one gains quantitative information about the relative rate of synthesis (accumulation) of that protein under the different conditions tested. This method has been termed pSILAC (pulsed stable isotope labelling of proteins with amino acids in cell culture) (Figure 2) .
The resulting data reveal a number of interesting features of the effects of mTOR inhibitors on the synthesis of specific proteins. First, the effects of mTOR kinase inhibitors on the synthesis of specific proteins are always greater than those of rapamycin, consistent with the data for general protein synthesis. This implies that mTOR kinase inhibitors act to impair the general protein synthetic machinery. Thus the greater effect of the mTOR kinase inhibitors is not a consequence of a large effect only on the translation of certain mRNAs.
Secondly, as expected from the results for overall protein synthesis, the inhibition by rapamycin was small for the majority of proteins that are not encoded by 5 -TOP mRNAs. Among such proteins, only a few were strongly inhibited by rapamycin (see also below).
Thirdly, for the proteins encoded by 5 -TOP mRNAs, the degree of inhibition by rapamycin or mTOR kinase inhibitors was much greater than for almost all 'non-TOP' mRNAencoded proteins. The latter compounds had a profound effect on the synthesis of such proteins, with synthesis of around three-quarters of them being inhibited by >75 %. Rapamycin had a markedly smaller effect, with <10 % of such proteins' synthesis inhibited to this extent. Thus importantly, the translation of 5 -TOP mRNAs is regulated by mTOR in a manner that is in large part unaffected by rapamycin. This is consistent with studies showing that the translation of such mRNAs is not mediated by the S6Ks or phosphorylation of S6, which are inhibited similarly by rapamycin and mTOR kinase inhibitors [4, 16] . The fact that synthesis of such proteins is inhibited by rapamycin implies that this difference is not due to the distinct effects of mTOR kinase inhibitors or rapamycin on eIF4E/eIF4G binding, since rapamycin did not affect this. It is puzzling that in the case of some ribosomal proteins encoded by 5 -TOP mRNAs, no inhibition by rapamycin was observed, although mTOR kinase inhibitors did strongly impair the synthesis of these proteins.
Fourthly, synthesis of some proteins which are not known to be encoded by 5 -TOP mRNAs was also strongly (>50 %) inhibited by mTOR kinase inhibitors and quite strongly by rapamycin (typically approx. 30 %). Inspection of the 5 -end of the likely transcript (based on data from the DataBase of Transcriptional Start Sites; http://dbtss.hgc.jp/) revealed that a number of them contain sequences resembling a 5 -TOP at their extreme 5 -end. They may therefore be novel members of the class of 5 -TOP mRNAs, adding to the list of such mRNAs, which encode proteins involved in mRNA translation as well as ribosomal proteins [17] . Further analysis is clearly required to evaluate this. Finally, we found that the synthesis of several proteins involved in biosynthetic processes and other metabolic pathways was strongly inhibited by rapamycin or mTOR kinase inhibitors. That the synthesis of such proteins is positively regulated by mTORC1 would be consistent with the role of this pathway in promoting many anabolic processes (see, e.g., [18] ). Interestingly, these proteins do not appear to be encoded by 5 -TOP mRNAs, suggesting that other features confer control by mTORC1 upon these mRNAs.
Concluding remarks
Overall, our results show that signalling through mTOR (probably mTORC1) regulates the synthesis of almost all proteins, although in many cases the effects of rapamycin are quite small. Further analysis of the pSILAC data will probably reveal other interesting features of the effects of rapamycin and mTOR kinase inhibitors on the 'translatome'. Clearly, further work is needed to resolve a number of key questions, which include the following.
Why is the phosphorylation and regulation of 4E-BP1 unaffected by rapamycin in some cell types?
What is the overall impact of inhibition of eIF4E/eIF4G binding on the synthesis of specific proteins?
How do mTOR kinase inhibitors affect general protein synthesis? Which mTOR effectors are involved?
How does mTOR regulate the translation of 5 -TOP mRNAs, and why do mTOR kinase inhibitors have a much greater effect than rapamycin?
